May increase some pancreatic cancer survival rates
Neratinib and trastuzumab emtansine (T-DM1) combination potent and well tolerated
Maciejewski honored for work in bone marrow failure syndromes
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Results suggest: Offer broad testing to all of them
Clinical efficacy uncompromised in previously untreated patients
Clinical trials testing olaparib in breast cancer
Finding has potential to improve treatment
Survival for months or several years while delaying treatment is possible
More efficient, safer therapy may be on horizon
Advertisement
Advertisement